News

We are pleased to announce that process and operational changes have been made to transition Cancer Drug Implementation Advisory Committee (CDIAC) functions to CADTH effective July 1, 2019.  These changes will further enhance the transparency of the CADTH pan-Canadian Oncology Drug Review (pCODR) review process and better support public pay...

See Pharmaceutical Reviews Update – Issue 8 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include: details around when patient groups may be re-engaged in the CADTH Common Drug Review (CDR) process following an initial call for patient input an announcement on a...

Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.

See Pharmaceutical Reviews Update – Issue 7 for important news and information regarding CADTH’s drug review programs. This issue includes changes to the CADTH Common Drug Review procedure to include an additional embargo period for CDEC recommendations that have been substantially revised following a request for reconsiderat...

CADTH is pleased to announce the appointment of Dr. Nicole Mittmann, MSc., PhD, as CADTH Chief Scientist and Vice-President of Evidence Standards. Dr. Mittmann will lead CADTH’s shared science groups, including our Health Economics, Research Information Services, and Scientific Affairs teams. She will also be responsible for building networks w...